Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FiTNEss: IRD Induction and Maintenance in Myeloma
NCT03720041Phase 3Unknown
- Sponsor
- University of Leeds
- Start
- Aug 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ixazomib in multiple myeloma (MM), sponsored by University of Leeds. Status: unknown.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03720041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03720041.